Jazz Pharmaceuticals (NASDAQ:JAZZ) Downgraded to “Neutral” Rating by Cantor Fitzgerald

Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) from an overweight rating to a neutral rating in a research report sent to investors on Wednesday morning, MarketBeat Ratings reports. The firm currently has $150.00 price target on the specialty pharmaceutical company’s stock, up from their prior price target of $140.00.

A number of other analysts also recently weighed in on JAZZ. Morgan Stanley upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $140.00 to $175.00 in a research report on Thursday, December 12th. Wells Fargo & Company upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $130.00 to $170.00 in a research report on Thursday, February 13th. Royal Bank of Canada cut their price target on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a research report on Wednesday. Piper Sandler reiterated an “overweight” rating and issued a $176.00 price target (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday. Finally, Needham & Company LLC increased their price target on shares of Jazz Pharmaceuticals from $205.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $182.47.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock opened at $144.17 on Wednesday. The company has a market cap of $8.72 billion, a PE ratio of 20.31, a PEG ratio of 1.04 and a beta of 0.56. The company’s 50-day moving average is $125.42 and its two-hundred day moving average is $118.44. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals has a 1 year low of $99.06 and a 1 year high of $148.06.

Insider Transactions at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 2,000 shares of the firm’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $121.17, for a total value of $242,340.00. Following the completion of the transaction, the chief executive officer now directly owns 427,025 shares of the company’s stock, valued at approximately $51,742,619.25. This trade represents a 0.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 5,053 shares of company stock valued at $617,442 in the last ninety days. 4.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Bessemer Group Inc. grew its stake in shares of Jazz Pharmaceuticals by 0.3% in the fourth quarter. Bessemer Group Inc. now owns 26,932 shares of the specialty pharmaceutical company’s stock valued at $3,317,000 after buying an additional 92 shares in the last quarter. CIBC Asset Management Inc lifted its holdings in Jazz Pharmaceuticals by 5.2% during the 4th quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company’s stock valued at $243,000 after purchasing an additional 97 shares during the last quarter. Synovus Financial Corp lifted its holdings in Jazz Pharmaceuticals by 0.5% during the 4th quarter. Synovus Financial Corp now owns 19,206 shares of the specialty pharmaceutical company’s stock valued at $2,365,000 after purchasing an additional 100 shares during the last quarter. Quarry LP lifted its holdings in Jazz Pharmaceuticals by 6.3% during the 4th quarter. Quarry LP now owns 1,700 shares of the specialty pharmaceutical company’s stock valued at $209,000 after purchasing an additional 100 shares during the last quarter. Finally, Quadrant Capital Group LLC lifted its holdings in Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after purchasing an additional 101 shares during the last quarter. 89.14% of the stock is owned by institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.